Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
about
The indications for allogeneic stem cell transplantation in myeloid malignancies.Quality control and assurance in hematopoietic stem cell transplantation data registries in Japan and other countries.Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.Clinical and biological predictors of outcome following relapse of CML post-allo-SCTThe role of stem cell transplantation for chronic myelogenous leukemia in the 21st centuryOutcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort AnalysisBCR-ABL1 transcripts (MR4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia.CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML.Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.Is there a role for allogeneic transplantation in chronic myeloid leukemia?Omacetaxine mepesuccinate in chronic myeloid leukemia.The role of hematopoietic stem cell transplantation in chronic myeloid leukemia.Management of advanced-phase chronic myeloid leukemia.Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.Allogeneic transplantation for CML in the TKI era: striking the right balance.Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase.Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.Gut Microbiota Predict Pulmonary Infiltrates after Allogeneic Hematopoietic Cell Transplantation.Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis.Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors.Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link?Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors?Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.Optimal management for pediatric chronic myeloid leukemia.
P2860
Q30316611-F44FB551-0A68-4B53-BDAF-015369BC6405Q31022472-D8C29340-AEFF-4656-B9BF-15ECB05FC641Q33747792-5CCBFF39-DE43-40F2-9D36-0A7B3C0D0954Q35054717-C03A11F7-C025-4FCA-8BF0-88553D0D7F12Q35634865-64B2B692-1740-425F-8880-197A5595B859Q36928803-F7617BA4-F840-4FF8-83C0-0B7D8ECE887BQ37559148-8A5F1AFA-CB1B-4BD8-B470-5B77680B5102Q37611172-C2C36CD9-D69D-4F10-AE85-C5D5AF25BB29Q38139571-0427F077-0F31-4B24-A71B-60B9D4A1E412Q38161964-6A703AFE-5AFB-4619-8E20-AE1D25DC6FFBQ38258641-D4C75313-8223-406C-A757-42BF3155161CQ38392690-BFF163AD-62A4-45D7-A451-CF19A9F2D9A8Q38452040-C926EA93-B083-4EC4-BF28-A410080066AAQ38585916-6CC150B3-91AB-4F21-AC6B-42C49AF045ECQ38634736-27FF1040-FD69-4391-B78C-8B9401719C7DQ38725483-0E21570D-9EBA-4C3A-96EF-6A64250CA8E9Q38757051-76F90C40-405B-4AAD-9D08-62DCBF68B8F2Q38767908-B44F5954-57D0-435D-9002-BCA36DBFB92BQ38845834-4CE4EA7B-012B-4117-A1E6-07127C2EA700Q40787967-E2240C02-3B8F-4127-9ED9-26CBD460D5AFQ41649368-D88D516C-1FB3-4F2B-BBAF-0ABBEE4A64CEQ42203455-9046FB73-7AD5-43B2-951D-E5DF564AB830Q43719917-38E6F490-CD22-4C5A-B803-5631DC7390AFQ45199223-EB749A37-B777-4F92-9E8B-8D26E6308E18Q46737739-D79ECD0B-EE07-44D2-A8A5-63E4DC689747Q53004940-0363C352-B089-439F-83F5-E668B5F72539Q54347294-5EB8C405-CA1E-4983-A024-F54A8EC34F1EQ55001634-CD3986F2-ACAB-4639-A471-B34284898710Q55034870-02CB1321-B567-4B2E-BEA9-665038998B94
P2860
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 October 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prognostic factors for outcome ...... atinib era: a CIBMTR analysis.
@en
Prognostic factors for outcome ...... atinib era: a CIBMTR analysis.
@nl
type
label
Prognostic factors for outcome ...... atinib era: a CIBMTR analysis.
@en
Prognostic factors for outcome ...... atinib era: a CIBMTR analysis.
@nl
prefLabel
Prognostic factors for outcome ...... atinib era: a CIBMTR analysis.
@en
Prognostic factors for outcome ...... atinib era: a CIBMTR analysis.
@nl
P2093
P2860
P356
P1476
Prognostic factors for outcome ...... atinib era: a CIBMTR analysis.
@en
P2093
A Woolfrey
D A Rizzieri
H J Khoury
J M Goldman
P2860
P2888
P304
P356
10.1038/BMT.2011.194
P407
P50
P577
2011-10-10T00:00:00Z